OncLive TV

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.

William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.

Teresa Caprice, PA-C, discusses the use of post-transplant cyclophosphamide to address disparities in transplant outcomes in racial and ethnic populations.

Sebastian Stintzing, MD, discusses treatment with fruquintinib plus best supportive care in the Q-TWIST analysis in metastatic colorectal cancer.

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Ilyas Sahin, MD, discusses an assessment of the Northstar Response in patients with advanced gastrointestinal cancer undergoing active treatment.

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Francesco Di Meo, PhD, discusses the potential efficacy of CAR T-cells targeting the immunoreceptor LILRB4 in multiple myeloma.

Sarah Crafton, MD, discusses the integration of mirvetuximab soravtansine-gynx into clinical practice in the treatment of ovarian cancer.

Bhagirathbhai Dholaria, MBBS, discusses the ongoing evaluation of noncovalent BTK inhibitors in patients with chronic lymphocytic leukemia.

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

David Samuel Dicapua Siegel, MD, emphasizes the importance of real-world evidence when treating patients with relapsed/refractory multiple myeloma.

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.